Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822761 | 0.94 | APP (0.37) | PELI1NFE2L2ESR1KCNA3APP | |
| SCHEMBL10302939 | 0.88 | PTGS1 (0.35) | NFE2L2PTGS1PTGS2KCNA3APP | |
| SCHEMBL12823723 | 0.85 | MEN1 (0.39) | PTGS2ESR1APPMAPT | |
| SCHEMBL12823685 | 0.84 | KCNA3 (0.31) | KCNA3 | |
| SCHEMBL12821288 | 0.84 | KCNA3 (0.31) | KCNA3 | |
| SCHEMBL12821294 | 0.84 | CYP17A1 (0.40) | ESR1KCNA3CYP3A4 | |
| SCHEMBL10302927 | 0.83 | TUBB1 (0.35) | NFE2L2PTGS1PTGS2KCNA3 | |
| SCHEMBL12823421 | 0.83 | KDM1A (0.39) | PELI1NFE2L2PTGS1PTGS2KCNA3 | |
| SCHEMBL12719057 | 0.83 | KCNA3 (0.31) | NFE2L2KCNA3 | |
| SCHEMBL10302909 | 0.82 | ESR1 (0.37) | PELI1NFE2L2ESR1KCNA3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | PELI1 1762/4885NFE2L2 1574/4885PTGS1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.